Galmed Pharmaceuticals (GLMD) EBITDA (2013 - 2025)

Galmed Pharmaceuticals' EBITDA history runs 13 years deep, the most recent figure standing at $1.1 million for Q1 2025.

• In Q1 2025, EBITDA fell 14.97% year-over-year to $1.1 million; the TTM figure through Mar 2025 stood at -$7.5 million (down 7.74% YoY), while the FY2025 annual figure was -$10.2 million, down 36.33% from the prior year.
• EBITDA was $1.1 million for Q1 2025 at Galmed Pharmaceuticals, up from -$11.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $9.0 million in Q1 2021 to a low of -$58.3 million in Q4 2021.
• Historically, EBITDA has averaged -$6.1 million across 5 years, with a median of $1.4 million in 2023.
• The sharpest annual moves came in 2021 and 2023: EBITDA jumped 99.68% in 2021, then slumped 73.74% in 2023.
• A 5-year view of EBITDA shows it stood at -$58.3 million in 2021, then jumped by 41.01% to -$34.4 million in 2022, then jumped by 66.89% to -$11.4 million in 2023, then retreated by 2.6% to -$11.7 million in 2024, then soared by 109.29% to $1.1 million in 2025.
• The last three EBITDA figures came in at $1.1 million (Q1 2025), -$11.7 million (Q4 2024), and $1.8 million (Q3 2024), per Business Quant data.